跳至主要内容
临床试验/ACTRN12615001199505
ACTRN12615001199505已完成4 期

A field trial investigating the feasibility and safety of co-administration of azithromycin and ivermectin mass drug administration (MDA) for scabies and trachoma.

Murdoch Childrens Research Institute0 个研究点目标入组 25,000 人开始时间: 2015年11月4日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
25,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • All community members resident in Choiseul province, Solomon Islands able to be included in the study. Treatment is offered to all individuals regardless of the presence/absence of scabies/impetigo/trachoma at the time of MDA.

排除标准

  • - Allergy to any of the components of the allocated drug regimen
  • - Currently on, or has taken ivermectin in the previous 7 days
  • - Clinical diagnosis of crusted scabies: participants with severe or crusted scabies will be treated with 2 doses of ivermectin (except if ivermectin is contraindicated as outlined above) in conjunction with twice weekly permethrin cream for 1 month, with review at 1,2,3,12 and 24 months. Efforts will be made to control these cases intensively to prevent the high force of infection associated with these crusted cases from diminishing the effect of the MDA.

研究者

相似试验